


CLAIMS

1.- Use of ketolides and pharmaceutically acceptable salts thereof for the preparation of pharmaceutical compositions intended for preventing arterial thrombotic complications associated with atherosclerosis.

2.- Use according to Claim 1, characterized in that the ketolide corresponds to formula (I) :



in which R represents a radical

in which

- m represents the number 0 or 1,
- n represents the number 0 or 1,
- X represents a radical $(\text{NH})_a$, CH_2 or SO_2 with a
- 30 representing the number 0 or 1,
- Y represents a radical $(\text{CH}_2)_b-(\text{CH}=\text{CH})_c-(\text{CH}_2)_d$ with
- $c = 0$ or 1 and $b + c + d \leq 8$,
- Z represents a hydrogen or halogen atom,
- Ar represents an optionally substituted aryl or
- 35 heteroaryl radical:

11
The method of claim 1 wherein

3.- ~~Use according to Claim 1 or 2, characterized in that the~~
ketolide is 11,12-dideoxy-3-de[(2,6-dideoxy-3-C-methyl-3-O-
methyl-alpha-L-ribohexopyranosyl)oxy]-6-O-methyl-3-oxo-12,11-
([oxycarbonyl [[[2-[4-(3-pyridyl)-1H-imidazol-1-yl]ethoxy]-
5 methyl]imino]]erythromycin.

1
The method of claim 1 wherein
4.- ~~Use according to any one of Claims 1 to 3, characterized~~
in that the ketolide is 11,12-dideoxy-3-de((2,6-dideoxy-3-C-
methyl-3-O-methyl-alpha-L-ribohexopyranosyl)oxy)-6-O-methyl-
3-oxo-12,11-(oxycarbonyl((4-(3-(3-pyridyl)-1H-1,2,4-triazol-

10 1-yl)butyl)imino))erythromycin.
5.- ~~Use according to any one of Claims 1 to 3, characterized~~
in that the ketolide is 11,12-dideoxy-3-de((2,6-dideoxy-3-C-
methyl-3-O-methyl-alpha-L-ribohexopyranosyl)oxy)-2-fluoro-6-
O-methyl-3-oxo-12,11-(oxycarbonyl((4-(4-(3-pyridyl)-1H-
15 imidazol-1-yl)butyl)imino))erythromycin (A isomer).

1
The method of claim 1 wherein
6.- ~~Use according to any one of Claims 1 to 3, characterized~~
in that the ketolide is 11,12-dideoxy-3-de((2,6-dideoxy-3-C-
methyl-3-O-methyl-alpha-L-ribohexopyranosyl)oxy)-6-O-methyl-
3-oxo-12,11-(oxycarbonyl((4-(4-(3-pyridyl)-1H-imidazol-1-
20 yl)butyl)imino))erythromycin.

7.- Use according to any one of Claims 1 to 6, characterized
in that the ketolide is administered orally at a dose of
between 50 and 600 mg per day.

Add a2
add a4